Market Reports /
by Rachael Jones -
6 years ago
16 Nov 2018 - The ASX is set to open higher amid optimism that China and the US are seeking to resolve their trade spat. Wall St had a rollercoaster of a day. US stocks rose for th…
Company News /
by Rachael Jones -
6 years ago
12 Oct 2018 - Regenerative medicine comapny Mesoblast (ASX:MSB) today announced completion of the transaction with Tasly Pharmaceutical Group to establish a strategic partnership i…
Market Reports /
by Jessica Amir -
6 years ago
02 Oct 2018 - Market at Midday. ASX200 wipes out 3 months of gains and takes the market back to June levels. Rates to hold for 25th time. Most sectors lower. Mesoblast down 9.4% de…
Company Presentations /
by -
6 years ago
22 Aug 2018 - Mesoblast Limited (ASX:MSB) Head of Business Development and Licensing, David Oxley, presents details about the company's Phase 3 trials, its agreement with Tasly Chi…
Interviews /
by Rachael Jones -
6 years ago
22 Aug 2018 - Mesoblast Limited (ASX:MSB) Head, Business Development and Licensing, David Oxley, discusses the company's Phase 3 trials, its agreement with Tasly China and the near…
Stock Watch /
by -
6 years ago
23 Jul 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Australia and New Zealand Banking Group (ASX:ANZ), the ASX200, Doray Minerals (ASX:DRM), T…
Market Reports /
by Anna Napoli -
6 years ago
18 Jul 2018 - Australian shares are set to lift at the open, bolstered by gains on Wall Street overnight. Mesoblast (ASX:MSB) has inked a deal with Tasly Pharmaceutical Group.
Company News /
by Anna Napoli -
6 years ago
11 Jul 2018 - Cellular medicine company, Mesoblast (ASX:MSB) has announced that Shawn Cline Tomasello has joined its Board of Directors.
Market Reports /
by Rachael Jones -
6 years ago
19 Jun 2018 - The Australian share market has seen its strong advance falter after President Trump’s threat of new tariffs on China. It is still sitting above yesterday's close des…
Company News /
by Jessica Amir -
6 years ago
31 May 2018 - Mesoblast (ASX:MSB) reports after tax loss of US$14.5 million in the nine months to 31 March 2018, an improvement of 71 per cent. It also bumps up revenue and R&D spe…
Market Reports /
by Jessica Amir -
6 years ago
29 May 2018 - Market Wrap. ASX claws back some of yesterdays loses. Lithium players charged ahead today with Galaxy Resources (ASX:GXY) and Orocobre (ASX:ORE) taking the first and …
Company News /
by Anna Napoli -
6 years ago
29 May 2018 - Cellular medicine company, Mesoblast (ASX:MSB) has partnered with Cartherics to develop an off the shelf treatment for solid cancer.
Market Reports /
by Jessica Amir -
6 years ago
08 May 2018 - Market at Midday: ASX200 back at 10-year highs. Retail trade remained steady in March in seasonally adjusted terms, disappointing economists who expected a rise of 0.…
Company News /
by Rachael Jones -
6 years ago
18 Apr 2018 - Mesoblast Limited (ASX:MSB; Nasdaq:MESO) is looking to accelerate their entry for product MPC-150-IM into the cardiovascular market after an successful set of on-goin…
Stock Watch /
by -
6 years ago
16 Apr 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Galaxy Resources, Afterpay Touch Group, Woodside Petroleum and Mesoblast.
Company News /
by Anna Napoli -
7 years ago
07 Mar 2018 - Regenerative medical company Mesoblast (ASX:MSB) has entered into a $75 million non-dilutive four year credit facility with Hercules Capital.
Stock Watch /
by -
7 years ago
05 Mar 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Mesoblast, Xero, BHP Billiton, Twitter Inc, Nearmap and Wesfarmers.
Stock Watch /
by -
7 years ago
26 Feb 2018 - Fairmont Equities managing director Michael Gable takes a technical look at Sandfire Resources NL (ASX:SFR), Mesoblast (ASX:MSB), Genworth Mortgage Insurance Australi…
Market Reports /
by Jessica Amir -
7 years ago
21 Dec 2017 - Market at Midday: 60 per cent of the sectors trading below the line at noon. Property taking biggest hit after Charter Hall Group (ASX:CHC) fell 2.6 per cent. Treasur…
Company News /
by Kathy Skantzos -
7 years ago
15 Dec 2017 - Developer of innovative cell-based medicines Mesoblast (ASX:MSB) grants biopharmaceutical company TiGenix an exclusive global patent license that enables the global c…
Market Reports /
by Jessica Amir -
7 years ago
08 Dec 2017 - Market Wrap: Positive day of trade today, ASX200 0.3 per cent higher on Friday, 5 points up on week. Fairfax (ASX:FXJ) saw the most steam closing 5.7 per cent higher,…
Market Reports /
by Jessica Amir -
7 years ago
08 Dec 2017 - Market at Midday: Energy and Telcos gain, while traders sit on the fence awaiting China trade data. ASX200 0.28% higher at noon. Australia’s largest insurance broking…
Market Reports /
by Kathy Skantzos -
7 years ago
15 Nov 2017 - Market Outlook in 3 mins: Wall Street finishes in the red as GE shares continued 2-day fall. ASX set for a slower start, while it’s still sitting not far below the 59…
Market Reports /
by Jessica Amir -
7 years ago
28 Sep 2017 - Market close: ASX200 recovered from selling in Materials. Iron ore price almost 4 per cent. Utilities outperformed. Karoon Gas Australia (ASX:KAR) awarded a prospecti…
Company News /
by Jessica Amir -
7 years ago
28 Sep 2017 - Mesoblast (ASX:MSB) enrolled 159-patients into its clinical trial for cell therapy on end-stage heart failure.